SPOTLIGHT -
Allergan's brimonidine tartrate (Alphagan) will have new labeling that indicates its 0.5% strength is suitable for pediatric patients over 2 years old.
Dopavision reports positive results from MyopiaX-1 trial on pediatric myopia management
ROP: Treating and preventing blindness in preterm babies
ARVO 2024: Using objective measures to gauge activity levels of visually-impaired children
Managing a changing landscape of IRD pediatric cases
Keratoconus in a pediatric population has higher prevalence than expected
Intra-anterior chamber injection of ranibizumab a potentially relatively safe treatment for advanced pediatric vitreoretinal diseases